Biggest Cardiology Stories of 2012 from Heart Wire – Interventional cardiology

Health Care Comments Off
  • Results of the FREEDOM trial regarding the treatment of diabetic patients with multivessel disease, as well as the results of the FAME II trial on the importance of ischemic documentation on outcomes after PCI.
  • IABP SHOCK II trial, which had interesting insights with regard to how we treat cardiogenic-shock patients with PCI and the role of balloon-pump support in such cases.
  • In 2013, the initiation of a MitraClip trial in inoperable patients will reenergize the subject of percutaneous mitral-valve repair.
  • More durability data for the transcatheter aortic-valve technique with the results of the CoreValve trial as well as results in intermediate-risk patients treated with the Edwards device.
  • Results of the PARTNER II using the next-generation Sapien XT valve and lower-profile Novoflex delivery system (Edwards Lifesciences) are awaited.
  • The nonoperative patients in PARTNER II B are extremely high risk, but the randomized cohort, where patients are randomly assigned to surgical- or transcatheter-valve replacement, includes intermediate-risk patients with an STS score of 4 or higher. By contrast, in PARTNER I A, the average STS score was 11/12. That’s the biggest thing on the horizon in 2013.